| Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients (NCT00235560) | University Hospital, Toulouse | 2005-06-01 |
| T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) (NCT00242515) | National University Hospital, Singapore | 2005-03-01 |
| Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) (NCT00358644) | Eisai Inc. | 2005-03-01 |
| FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML (NCT00559221) | Cooperative Study Group A for Hematology | 2004-12-01 |
| Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML (NCT00529880) | Cooperative Study Group A for Hematology | 2004-12-01 |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00101179) | National Cancer Institute (NCI) | 2004-11-03 |
| Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation (NCT00460447) | University Hospital Carl Gustav Carus | 2004-10-01 |
| Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide (NCT00125606) | University Hospital Muenster | 2004-10-01 |
| Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia (NCT00279773) | Novartis Pharmaceuticals | 2004-09-01 |
| Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies (NCT00513318) | University of California, San Francisco | 2004-08-01 |
| Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). (NCT00088218) | M.D. Anderson Cancer Center | 2004-07-01 |
| Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00151242) | University of Ulm | 2004-07-01 |
| To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning (NCT00226512) | Hadassah Medical Organization | 2004-07-01 |
| Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia (NCT00086099) | MedImmune LLC | 2004-07-01 |
| A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable (NCT00924443) | Genzyme, a Sanofi Company | 2004-06-01 |
| All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00151255) | University of Ulm | 2004-06-01 |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies (NCT00145626) | St. Jude Children's Research Hospital | 2004-05-01 |
| HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk (NCT02461121) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2004-05-01 |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML (NCT00669890) | New York Medical College | 2004-05-01 |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers (NCT00089596) | ViaCell | 2004-03-01 |
| NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (NCT00476541) | University of Aarhus | 2004-01-01 |
| Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT00093990) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-01-01 |
| Study of Bexarotene in Patients With Acute Myeloid Leukemia (NCT00316030) | Abramson Cancer Center at Penn Medicine | 2004-01-01 |
| Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia (NCT00081822) | University of Alabama at Birmingham | 2004-01-01 |
| Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia (NCT00342316) | Vastra Gotaland Region | 2003-12-18 |
| Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission (NCT00150878) | University Hospital Carl Gustav Carus | 2003-12-01 |
| Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) (NCT00067028) | M.D. Anderson Cancer Center | 2003-12-01 |
| Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) (NCT00079482) | Cephalon | 2003-10-01 |
| Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00488709) | PETHEMA Foundation | 2003-05-01 |
| Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant (NCT00096161) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS (NCT00195000) | Weill Medical College of Cornell University | 2003-05-01 |
| Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia (NCT00866073) | University Hospital Freiburg | 2003-04-01 |
| High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML (NCT00774046) | University of Chicago | 2002-12-01 |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies (NCT00514722) | University of California, San Francisco | 2002-10-01 |
| Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML) (NCT00188136) | University Hospital Carl Gustav Carus | 2002-08-01 |
| A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. (NCT00300664) | Royal Marsden NHS Foundation Trust | 2002-07-01 |
| Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older (NCT00048503) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-06-01 |
| WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) (NCT00153582) | Charite University, Berlin, Germany | 2002-04-01 |
| Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia (NCT00186966) | Dutch Childhood Oncology Group | 2002-03-01 |
| PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) (NCT00045942) | Novartis Pharmaceuticals | 2002-01-30 |
| Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care (NCT00161668) | Wyeth is now a wholly owned subsidiary of Pfizer | 2001-10-01 |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia (NCT00513175) | University of California, San Francisco | 2001-10-01 |
| Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML (NCT00583102) | University of Iowa | 2001-06-01 |
| Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial (NCT02867891) | Robert Zeiser | 2001-03-01 |
| Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation (NCT01015196) | Nantes University Hospital | 2001-01-01 |
| Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia (NCT00037596) | Wyeth is now a wholly owned subsidiary of Pfizer | 2000-08-01 |
| T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (NCT00368355) | Baylor College of Medicine | 2000-04-01 |
| Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (NCT01499147) | University of Illinois at Chicago | 2000-02-01 |
| Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience. (NCT03350152) | Hospices Civils de Lyon | 2000-01-01 |
| Efficacy of G-CSF-Priming in Elderly AML Patients (NCT00199147) | Johann Wolfgang Goethe University Hospital | 2000-01-01 |
| Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2 (NCT00931138) | Acute Leukemia French Association | 1999-12-01 |
| A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. (NCT00363025) | Acute Leukemia French Association | 1999-11-01 |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia (NCT00171249) | Novartis Pharmaceuticals | 1999-08-09 |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) (NCT00266136) | University Hospital Muenster | 1999-06-01 |
| Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies (NCT00038051) | M.D. Anderson Cancer Center | 1999-05-01 |
| Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) (NCT00880243) | Acute Leukemia French Association | 1999-03-01 |
| L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT00329498) | Samsung Medical Center | 1998-05-01 |
| Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result (NCT00146120) | University of Ulm | 1998-05-01 |
| Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel (NCT00159003) | Deborah Rund | 1998-01-01 |
| GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly (NCT00925873) | French Innovative Leukemia Organisation | 1996-06-01 |
| Lomustine and Intermediate Dose Cytarabine in Older Patients With AML (NCT00480064) | French Innovative Leukemia Organisation | 1995-07-01 |
| Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission (NCT00667927) | St. Jude Children's Research Hospital | 1991-03-01 |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS (NCT05593185) | Sellas Life Sciences Group | |
| Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant (NCT01200017) | Christopher Dvorak | |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies (NCT07346105) | Orca Biosystems, Inc. | |
| Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation (NCT03245424) | Agios Pharmaceuticals, Inc. | |
| Expanded Access to ABBV-787 (NCT06439966) | AbbVie | |
| Expanded Access for AG-221 (NCT03723057) | Celgene | |
| Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation (NCT02258490) | Emory University | |
| Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia (NCT01039363) | Samsung Medical Center | |
| Managed Access Programs for PKC412, Midostaurin (NCT05219266) | Novartis Pharmaceuticals | |
| Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image (NCT00172562) | National Taiwan University Hospital | |
| Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (NCT00037583) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Flotetuzumab Expanded Access Program (NCT04678466) | MacroGenics | |